Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers

将嵌合抗原 (CAR) T 细胞疗法扩展到胸部癌症

基本信息

  • 批准号:
    10241975
  • 负责人:
  • 金额:
    $ 210.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-14 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Overall Summary The goal of this Program Project is to develop approaches to reproduce the success of adoptive T cell transfer using chimeric antigen receptor (CAR) transduced T cells for hematologic malignancies to solid tumors, with a focus on thoracic malignancies (non-small cell lung cancer [NSCLC] and malignant pleural mesothelioma [MPM]. An important scientific theme in all of the projects is an exploration of the ability of CAR T cells to induce epitope spreading, that is, their ability to stimulate endogenous B and T cell responses against the tumor- a key component for success in solid tumors. This PO1 will have 3 projects which will be supported by 3 Cores. Project 1 will conduct clinical trials using CAR T cells. In Aim 1, we will continue a clinical trial in patients with NSCLC and MPM using a newly designed and improved anti-mesothelin-CAR construct. In Aim 2, we will conduct a Phase 1 clinical trial to evaluate the potential safety and clinical activity of a CAR targeted to tumor stroma (cancer associated fibroblasts) by engaging fibroblast activation protein (FAP). In future studies, we will design a third CAR T cell trial based on the results of these two trials and on new data from Projects 2 and 3. Project 2 will study ways to overcome heterogeneity in solid tumor CAR T cell therapy using preclinical studies that will integrate closely with our planned clinical trials. In Aim 1, we will conduct studies to evaluate the safety and efficacy of targeting tumor stroma using CARs targeted against anti-human fibroblast activation protein (FAP). In Aim 2, we will explore the key issue of mesothelin and FAP CARs being able to induce bystander effects and epitope spreading. In Aim 3, we will examine ways to augment this. Project 3 will conduct human biocorrelative studies. In Aim 1, we will study the persistence,trafficking, and function of CAR T cells in tumors. In Aim 2, we will evaluate the hypothesis that the CAR T cells used in our clinical trials can activate endogenous anti-tumor CD8 T cell responses (similar to the studies in Project 2). In Aim 3, we will characterize the polyclonality of T cell responses generated by epitope spreading after CAR T cell infusion in peripheral blood and tumors. We will benefit greatly from the unique environment of the newly established Penn Center for Cellular Immunotherapies (CCI) led by Dr. Carl June. These projects will be supported by an Administrative Core (with an internal and external advisory board), a Pathology/Sample Acquisition Core, and a Biostatistics/Bioinformatics/Data Management Core. Monthly Program Project meetings will be held. The PO1 has highly experienced leadership and the Project leaders and Core leaders have long track records of successful collaborations and publications. Each project is highly dependent on the other projects, requiring the Program Project format for success. The PO1 has high significance: achieving success rates with CAR T cells in solid tumors similar to that seen in leukemia would be a major paradigm shift in the treatment of solid tumors. 1
总体摘要 该计划项目的目标是开发复制采用T细胞转移的成功的方法 利用嵌合抗原受体(CAR)转导的T细胞治疗恶性血液病到实体瘤 重点关注胸部恶性肿瘤(非小细胞肺癌和恶性胸膜间皮瘤) [MPM]。所有项目中的一个重要科学主题是探索CAR T细胞 诱导表位扩散,即它们刺激内源性B和T细胞对 肿瘤--实体肿瘤治疗成功的关键因素。此PO1将有3个项目,将由 3核。项目1将使用CAR T细胞进行临床试验。在目标1中,我们将继续在 非小细胞肺癌和MPM患者使用新设计和改进的抗间皮蛋白-CAR结构。在AIM 2、我们将进行第一阶段临床试验,以评估靶向CAR的潜在安全性和临床活性 通过结合成纤维细胞激活蛋白(FAP)对肿瘤间质(肿瘤相关成纤维细胞)进行诱导。在未来 研究,我们将根据这两个试验的结果和来自 项目2和项目3。项目2将研究如何克服实体瘤CAR T细胞治疗中的异质性 临床前研究将与我们计划的临床试验紧密结合。在目标1中,我们会进行研究,以 靶向抗人成纤维细胞的CARS靶向肿瘤间质的安全性和有效性评价 激活蛋白(FAP)。在目标2中,我们将探讨Mesothelin和FAP CARS能够 引发旁观者效应和表位扩散。在目标3中,我们将研究加强这一点的方法。项目3 将进行人体生物相关研究。在目标1中,我们将研究持续、贩运和功能 肿瘤中的CAR T细胞。在目标2中,我们将评估临床试验中使用的CAR T细胞的假设 可以激活内源性抗肿瘤CD8 T细胞反应(类似于项目2中的研究)。在《目标3》中,我们将 Car T细胞输注后表位扩散所致T细胞应答的多克隆性特征 外周血和肿瘤。我们将从新成立的独特环境中受益匪浅 由卡尔·琼博士领导的宾夕法尼亚大学细胞免疫疗法中心(CCI)。这些项目将由一个 行政核心(有内部和外部咨询委员会)、病理学/样本采集核心、 和一个生物统计/生物信息学/数据管理核心。将举行每月计划项目会议。 PO1有非常丰富的领导经验,项目负责人和核心负责人有长期的记录 成功的合作和出版物。每个项目都高度依赖于其他项目,需要 成功的计划项目格式。PO1具有很高的意义:使用CAR T实现成功率 实体瘤中的细胞类似于白血病中的细胞,这将是实体瘤治疗中的重大范式转变 肿瘤。 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven Mark Albelda其他文献

Steven Mark Albelda的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven Mark Albelda', 18)}}的其他基金

Project 2 - Preclinical studies: Overcoming tumor heterogeneity
项目2 - 临床前研究:克服肿瘤异质性
  • 批准号:
    10006192
  • 财政年份:
    2018
  • 资助金额:
    $ 210.15万
  • 项目类别:
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
项目2 - 临床前研究:克服肿瘤异质性
  • 批准号:
    10241978
  • 财政年份:
    2018
  • 资助金额:
    $ 210.15万
  • 项目类别:
Core A - Administrative Core
核心 A - 行政核心
  • 批准号:
    10241980
  • 财政年份:
    2018
  • 资助金额:
    $ 210.15万
  • 项目类别:
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
将嵌合抗原 (CAR) T 细胞疗法扩展到胸部癌症
  • 批准号:
    10006051
  • 财政年份:
    2018
  • 资助金额:
    $ 210.15万
  • 项目类别:
Core A - Administrative Core
核心 A - 行政核心
  • 批准号:
    10006194
  • 财政年份:
    2018
  • 资助金额:
    $ 210.15万
  • 项目类别:
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells
TIM3和CEACAM1在人效应T细胞抗肿瘤功能中的作用
  • 批准号:
    10215429
  • 财政年份:
    2017
  • 资助金额:
    $ 210.15万
  • 项目类别:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
使用靶向肿瘤基质的基因工程 T 细胞治疗肺癌
  • 批准号:
    8578578
  • 财政年份:
    2013
  • 资助金额:
    $ 210.15万
  • 项目类别:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
使用靶向肿瘤基质的基因工程 T 细胞治疗肺癌
  • 批准号:
    9101792
  • 财政年份:
    2013
  • 资助金额:
    $ 210.15万
  • 项目类别:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
使用靶向肿瘤基质的基因工程 T 细胞治疗肺癌
  • 批准号:
    8739623
  • 财政年份:
    2013
  • 资助金额:
    $ 210.15万
  • 项目类别:
Genetic Influence on Incidence of Acute Lung Injury
遗传对急性肺损伤发生率的影响
  • 批准号:
    7796690
  • 财政年份:
    2009
  • 资助金额:
    $ 210.15万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 210.15万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 210.15万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了